Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients with Resistant Hypertension

Gianni Sesa-Ashton; Janis M. Nolde; Ida Muente; Revathy Carnagarin; Rebecca Lee; Vaughan G. Macefield; Tye Dawood; Yusuke Sata; Elisabeth A. Lambert; Gavin W. Lambert; Antony Walton; Marcio G. Kiuchi; Murray D. Esler; Markus P. Schlaich

doi:10.1161/HYPERTENSIONAHA.122.20853

Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients with Resistant Hypertension

Gianni Sesa-Ashton, Janis M. Nolde, Ida Muente, Revathy Carnagarin, Rebecca Lee, Vaughan G. Macefield, Tye Dawood, Yusuke Sata, Elisabeth A. Lambert, Gavin W. Lambert, Antony Walton, Marcio G. Kiuchi, Murray D. Esler, Markus P. Schlaich

Research output: Contribution to journal › Article › peer-review

51 Citations (Scopus)

Abstract

Background: Recent sham-controlled randomized clinical trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN). Long-term safety and efficacy data beyond 3 years are scarce. Here, we report on outcomes after RDN in a cohort of patients with resistant hypertension with an average of ≈9-year follow-up (FU). Methods: We recruited patients with resistant hypertension who were previously enrolled in various RDN trials applying radiofrequency energy for blood pressure (BP) lowering. All participants had baseline assessments before RDN and repeat assessment at long-term FU including medical history, automated office and ambulatory BP measurement, and routine blood and urine tests. We analyzed changes between baseline and long-term FU. Results: A total of 66 participants (mean±SD, 70.0±10.3 years; 76.3% men) completed long-term FU investigations with a mean of 8.8±1.2 years post-procedure. Compared with baseline, ambulatory systolic BP was reduced by -12.1±21.6 (from 145.2 to 133.1) mm Hg (P

Original language	English
Pages (from-to)	811-819
Number of pages	9
Journal	Hypertension
Volume	80
Issue number	4
DOIs	https://doi.org/10.1161/HYPERTENSIONAHA.122.20853
Publication status	Published - 1 Apr 2023

Access to Document

10.1161/HYPERTENSIONAHA.122.20853

Cite this

Sesa-Ashton, G., Nolde, J. M., Muente, I., Carnagarin, R., Lee, R., Macefield, V. G., Dawood, T., Sata, Y., Lambert, E. A., Lambert, G. W., Walton, A., Kiuchi, M. G., Esler, M. D., & Schlaich, M. P. (2023). Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients with Resistant Hypertension. Hypertension, 80(4), 811-819. https://doi.org/10.1161/HYPERTENSIONAHA.122.20853

@article{1d6bafe891834243b2a7b54a59245c90,

title = "Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients with Resistant Hypertension",

abstract = "Background: Recent sham-controlled randomized clinical trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN). Long-term safety and efficacy data beyond 3 years are scarce. Here, we report on outcomes after RDN in a cohort of patients with resistant hypertension with an average of ≈9-year follow-up (FU). Methods: We recruited patients with resistant hypertension who were previously enrolled in various RDN trials applying radiofrequency energy for blood pressure (BP) lowering. All participants had baseline assessments before RDN and repeat assessment at long-term FU including medical history, automated office and ambulatory BP measurement, and routine blood and urine tests. We analyzed changes between baseline and long-term FU. Results: A total of 66 participants (mean±SD, 70.0±10.3 years; 76.3% men) completed long-term FU investigations with a mean of 8.8±1.2 years post-procedure. Compared with baseline, ambulatory systolic BP was reduced by -12.1±21.6 (from 145.2 to 133.1) mm Hg (P",

keywords = "blood pressure, hypertension, renal denervation, renal function, sympathetic nervous system",

author = "Gianni Sesa-Ashton and Nolde, {Janis M.} and Ida Muente and Revathy Carnagarin and Rebecca Lee and Macefield, {Vaughan G.} and Tye Dawood and Yusuke Sata and Lambert, {Elisabeth A.} and Lambert, {Gavin W.} and Antony Walton and Kiuchi, {Marcio G.} and Esler, {Murray D.} and Schlaich, {Markus P.}",

note = "Funding Information: This study was supported by Medtronic. Funding Information: M.P. Schlaich has received support from an National Health and Medical Research Council (NHMRC) Research Fellowship and research support from Medtronic, Abbott, and Servier Australia. He serves on scientific advisory boards for Abbott, Boehringer Ingelheim, Servier, Novartis, and Medtronic. A. Walton is a Proctor for Medtronic and Abbott, is on the Medical Advisory Board of Medtronic, and receives grant support from Medtronic, Abbott, and Edwards. M.D. Esler and G.W. Lambert have received consulting fees and travel and research support from Medtronic. The other authors report no conflicts. Publisher Copyright: {\textcopyright} 2023 Lippincott Williams and Wilkins. All rights reserved.",

year = "2023",

month = apr,

day = "1",

doi = "10.1161/HYPERTENSIONAHA.122.20853",

language = "English",

volume = "80",

pages = "811--819",

journal = "Hypertension",

issn = "0194-911X",

publisher = "Lippincott Williams & Wilkins",

number = "4",

}

Sesa-Ashton, G, Nolde, JM, Muente, I, Carnagarin, R, Lee, R, Macefield, VG, Dawood, T, Sata, Y, Lambert, EA, Lambert, GW, Walton, A, Kiuchi, MG, Esler, MD & Schlaich, MP 2023, 'Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients with Resistant Hypertension', Hypertension, vol. 80, no. 4, pp. 811-819. https://doi.org/10.1161/HYPERTENSIONAHA.122.20853

TY - JOUR

T1 - Catheter-Based Renal Denervation

T2 - 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients with Resistant Hypertension

AU - Sesa-Ashton, Gianni

AU - Nolde, Janis M.

AU - Muente, Ida

AU - Carnagarin, Revathy

AU - Lee, Rebecca

AU - Macefield, Vaughan G.

AU - Dawood, Tye

AU - Sata, Yusuke

AU - Lambert, Elisabeth A.

AU - Lambert, Gavin W.

AU - Walton, Antony

AU - Kiuchi, Marcio G.

AU - Esler, Murray D.

AU - Schlaich, Markus P.

N1 - Funding Information: This study was supported by Medtronic. Funding Information: M.P. Schlaich has received support from an National Health and Medical Research Council (NHMRC) Research Fellowship and research support from Medtronic, Abbott, and Servier Australia. He serves on scientific advisory boards for Abbott, Boehringer Ingelheim, Servier, Novartis, and Medtronic. A. Walton is a Proctor for Medtronic and Abbott, is on the Medical Advisory Board of Medtronic, and receives grant support from Medtronic, Abbott, and Edwards. M.D. Esler and G.W. Lambert have received consulting fees and travel and research support from Medtronic. The other authors report no conflicts. Publisher Copyright: © 2023 Lippincott Williams and Wilkins. All rights reserved.

PY - 2023/4/1

Y1 - 2023/4/1

N2 - Background: Recent sham-controlled randomized clinical trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN). Long-term safety and efficacy data beyond 3 years are scarce. Here, we report on outcomes after RDN in a cohort of patients with resistant hypertension with an average of ≈9-year follow-up (FU). Methods: We recruited patients with resistant hypertension who were previously enrolled in various RDN trials applying radiofrequency energy for blood pressure (BP) lowering. All participants had baseline assessments before RDN and repeat assessment at long-term FU including medical history, automated office and ambulatory BP measurement, and routine blood and urine tests. We analyzed changes between baseline and long-term FU. Results: A total of 66 participants (mean±SD, 70.0±10.3 years; 76.3% men) completed long-term FU investigations with a mean of 8.8±1.2 years post-procedure. Compared with baseline, ambulatory systolic BP was reduced by -12.1±21.6 (from 145.2 to 133.1) mm Hg (P

AB - Background: Recent sham-controlled randomized clinical trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN). Long-term safety and efficacy data beyond 3 years are scarce. Here, we report on outcomes after RDN in a cohort of patients with resistant hypertension with an average of ≈9-year follow-up (FU). Methods: We recruited patients with resistant hypertension who were previously enrolled in various RDN trials applying radiofrequency energy for blood pressure (BP) lowering. All participants had baseline assessments before RDN and repeat assessment at long-term FU including medical history, automated office and ambulatory BP measurement, and routine blood and urine tests. We analyzed changes between baseline and long-term FU. Results: A total of 66 participants (mean±SD, 70.0±10.3 years; 76.3% men) completed long-term FU investigations with a mean of 8.8±1.2 years post-procedure. Compared with baseline, ambulatory systolic BP was reduced by -12.1±21.6 (from 145.2 to 133.1) mm Hg (P

KW - blood pressure

KW - hypertension

KW - renal denervation

KW - renal function

KW - sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=85150155762&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.122.20853

DO - 10.1161/HYPERTENSIONAHA.122.20853

M3 - Article

C2 - 36762561

AN - SCOPUS:85150155762

SN - 0194-911X

VL - 80

SP - 811

EP - 819

JO - Hypertension

JF - Hypertension

IS - 4

ER -

Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients with Resistant Hypertension

Abstract

Access to Document

Other files and links

Fingerprint

Data science and cardiovascular risk

Cite this